LBG Joins Effort to Overcome the Challenges of Gene Therapy

Dr. Joe Rininger, Director, Cell and Gene Therapy, and Frank Orlowski, Director, Business Development, will attend Gene Therapy for Rare Disorders 2022 on March 7 – 10 at the Hynes Convention Center in Boston. As attendees at the conference, they will have the opportunity to engage in meaningful discussions with professionals from biotechs, large pharma, academia, and key service provider companies.

Dr. Rininger has more than 20 years of experience in basic biomedical research and biopharmaceutical product development, manufacturing, and program management with an emphasis on vaccines and gene therapy. At LBG, he leads product development engagements with cell and gene therapy companies, vaccine developers, and service providers and has also led multiple pre-IND and subsequent IND submissions for these therapeutics.

Mr. Orlowski leads LBG’s business development. A former Pfizer executive, he worked for more than 25 years in positions of increasing responsibility in Finance, Strategy, and Operations. He led the Supply Chain and Finance functions across Asia, Eastern Europe, South America, and the Middle East, developing business, operational, and financial market access product localization strategies.

The four-day conference, which is “the industry-leading event for companies developing gene therapies in the rare disease space,” offers insights and networking opportunities to accelerate progress in the gene therapy field.